3:30 PM
 | 
Apr 04, 2019
 |  BC Extra  |  Preclinical News

Nimbus exposes complete ACLY structure, discovers allosteric inhibitory sites

Nimbus is spinning out a subsidiary to develop ACLY inhibitors targeting a new allosteric site on the enzyme that it discovered in collaboration with Schrödinger and Columbia University.

BioCentury identified lipid biosynthesis regulator ACLY as an emerging metabolic target among abstracts for this year's meeting of the American Association for Cancer Research (AACR) (see "Next-wave Targets at AACR 2019 Start Filling the Blanks in the Tumor Microenvironment").

The metabolic...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >